Literature DB >> 25716744

Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status.

Pierre Bourdillon1, Chadi Hlaihel, Jacques Guyotat, Laurent Guillotton, Jérôme Honnorat, François Ducray, François Cotton.   

Abstract

The aim of this study was to assess whether combining multimodal magnetic resonance imaging (MRI) with the determination of the 1p/19q codeletion status could improve the ability to predict anaplastic transformation in low-grade oligodendrogliomas. Twenty patients with grade II oligodendrogliomas were followed-up using multimodal MR [proton MR spectroscopy (MRS), perfusion, and conventional MR imaging]. All patients diagnoses were histologically proven, and 1p/19q codeletion status was analyzed for all patients. Median follow-up was 30.5 ± 11.4 months. Anaplastic transformation was observed in six patients. The only MRI feature that was associated with anaplastic transformation was an elevation of the choline/creatine ratio >2.4 which was observed in 4 out of 6 patients with anaplastic transformation versus 1 out of 14 patients without anaplastic transformation. In patients without 1p/19q codeletion, an elevation of the choline/creatine ratio >2.4 was associated with the occurrence of anaplastic transformation in all cases (4 out of 4 patients), with a mean time of 12 months. In contrast, in patients with a 1p/19q codeletion, no anaplastic transformation was observed in the patient who had an elevation of >2.4 of the choline/creatine ratio and two patients demonstrated an anaplastic transformation without any elevation of this ratio.Prospective validation in a larger series is needed, yet the present study suggests that combining data from in vivo proton MRS and genetic analysis could be a promising strategy to predict time to anaplastic transformation at the individual level in patients with low-grade oligodendrogliomas and may help deciding when chemotherapy and/or radiotherapy should be initiated in these tumors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25716744     DOI: 10.1007/s11060-015-1737-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  48 in total

1.  Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study.

Authors:  Nadia N Laack; Paul D Brown; Robert J Ivnik; Alfred F Furth; Karla V Ballman; Julie E Hammack; Robert M Arusell; Edward G Shaw; Jan C Buckner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-20       Impact factor: 7.038

2.  Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study.

Authors:  M Klein; J J Heimans; N K Aaronson; H M van der Ploeg; J Grit; M Muller; T J Postma; J J Mooij; R H Boerman; G N Beute; G J Ossenkoppele; G W van Imhoff; A W Dekker; J Jolles; B J Slotman; H Struikmans; M J B Taphoorn
Journal:  Lancet       Date:  2002-11-02       Impact factor: 79.321

3.  Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Frank J Attenello; Jon D Weingart; Khoi Than; Peter C Burger; Alessandro Olivi; Henry Brem; Alfredo Quinoñes-Hinojosa
Journal:  Neurosurgery       Date:  2008-10       Impact factor: 4.654

4.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

5.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.

Authors:  K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

6.  Low-grade oligodendroglioma responds to chemotherapy.

Authors:  W P Mason; G S Krol; L M DeAngelis
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

7.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

8.  Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?

Authors:  Nasuda Danchaivijitr; Adam D Waldman; Daniel J Tozer; Christopher E Benton; Gisele Brasil Caseiras; Paul S Tofts; Jeremy H Rees; H Rolf Jäger
Journal:  Radiology       Date:  2008-04       Impact factor: 11.105

9.  Seizure characteristics and control following resection in 332 patients with low-grade gliomas.

Authors:  Edward F Chang; Matthew B Potts; G Evren Keles; Kathleen R Lamborn; Susan M Chang; Nicholas M Barbaro; Mitchel S Berger
Journal:  J Neurosurg       Date:  2008-02       Impact factor: 5.115

10.  Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells.

Authors:  S B Wharton; E Maltby; D A Jellinek; D Levy; N Atkey; S Hibberd; D Crimmins; K Stoeber; G H Williams
Journal:  Acta Neuropathol       Date:  2006-12-09       Impact factor: 17.088

View more
  6 in total

1.  Regional specificity of 1p/19q co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients.

Authors:  Kai Wang; Yinyan Wang; Xing Fan; Yanong Li; Xing Liu; Jiangfei Wang; Lin Ai; Jianping Dai; Tao Jiang
Journal:  J Neurooncol       Date:  2017-12-11       Impact factor: 4.130

Review 2.  Can artificial intelligence overtake human intelligence on the bumpy road towards glioma therapy?

Authors:  Precilla S Daisy; T S Anitha
Journal:  Med Oncol       Date:  2021-04-03       Impact factor: 3.064

3.  MRS as an Aid to Diagnose Malignant Transformation in Low-Grade Gliomas with Increasing Contrast Enhancement.

Authors:  C H Toh; M Castillo; K-C Wei; P-Y Chen
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-30       Impact factor: 3.825

4.  Early Detection of Malignant Transformation in Resected WHO II Low-Grade Glioma Using Diffusion Tensor-Derived Quantitative Measures.

Authors:  Martin T Freitag; Klaus H Maier-Hein; Francisczek Binczyk; Frederik B Laun; Christian Weber; David Bonekamp; Rafal Tarnawski; Barbara Bobek-Billewicz; Joanna Polanska; Henryk Majchrzak; Bram Stieltjes
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

5.  Integrative Network-based Analysis of Magnetic Resonance Spectroscopy and Genome Wide Expression in Glioblastoma multiforme.

Authors:  Dieter Henrik Heiland; Irina Mader; Pascal Schlosser; Dietmar Pfeifer; Maria Stella Carro; Thomas Lange; Ralf Schwarzwald; Ioannis Vasilikos; Horst Urbach; Astrid Weyerbrock
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

6.  Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence.

Authors:  Zeynettin Akkus; Issa Ali; Jiří Sedlář; Jay P Agrawal; Ian F Parney; Caterina Giannini; Bradley J Erickson
Journal:  J Digit Imaging       Date:  2017-08       Impact factor: 4.056

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.